Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer

Cancer

Volumn 119, Issue 14, 2013, Pages 2564-2573

  Innominato, Pasquale F ^a,b,c,d   Giacchetti, Sylvie ^a,b,c,e   Moreau, Thierry ^f   Bjarnason, Georg A ^g   Smaaland, Rune ^h   Focan, Christian ⁱ   Garufi, Carlo ^j   Iacobelli, Stefano ^k   Tampellini, Marco ^l   Tumolo, Salvatore ^m   Carvalho, Carlos ⁿ   Karaboué, Abdoulaye ^a,b   Poncet, Antoine ^a,b,p   Spiegel, David ^o   Lévi, Francis ^a,b,c  

^a INSERM   (France)

^b Medical Research Unit (UMR)   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d Paris South University   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^g DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^h UNIVERSITY OF BERGEN   (Norway)

ⁱ Clinique Saint Joseph   (Belgium)

^j REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^k UNIVERSITY OF CHIETI   (Italy)

^l SAN LUIGI GONZAGA HOSPITAL   (Italy)

^m S MARIA DEGLI ANGELI HOSPITAL   (Italy)

ⁿ F Fonseca Hospital   (Portugal)

^o STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF GENEVA   (Switzerland)

more..

Author keywords

chemotherapy; circadian; colorectal cancer; prognostic factor; toxicity

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; STEROID;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONOTHERAPY; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEMALE; GENDER BIAS; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

CHEMOTHERAPY; CIRCADIAN; COLORECTAL CANCER; PROGNOSTIC FACTOR; TOXICITY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG CHRONOTHERAPY; FATIGUE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGANOPLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84879691381     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28072     Document Type: Article

References (35)

1. Felici A, Verweij J, Sparreboom A,. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer. 2002; 38: 1677-1684.
2. Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I,. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer. 1997; 75: 301-305.
3. Cuzick J, Sestak I, Cella D, Fallowfield L,. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol. 2008; 9: 1143-1148.
4. Di Maio M, Gridelli C, Gallo C, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 3 randomised trials. Lancet Oncol. 2005; 6: 669-677.
5. Shitara K, Matsuo K, Takahari D, et al. Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. Eur J Cancer. 2009; 45: 1757-2763.
6. Gatzemeier U, von Pawel J, Vynnychenko I, et al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol. 2011; 12: 30-37.
7. Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011; 103: 763-773.
8. Zhu AX, Duda DG, Ancukiewicz M, et al. Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value. Clin Cancer Res. 2011; 17: 918-927.
9. Mayers C, Panzarella T, Tannock IF,. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer. 2001; 91: 2246-2257.
10. Innominato PF, Giacchetti S, Moreau T, et al. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-fluorouracil- leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). Chronobiol Int. 2011; 28: 586-600.
11. Giacchetti S, Bjarnason G, Garufi C, et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol. 2006; 24: 3562-3569.
12. Giacchetti S, Dugue PA, Innominato PF, et al. Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. Ann Oncol. 2012; 23: 3110-3116.
13. Levi F, Okyar A, Dulong S, Innominato PF, Clairambault J,. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 2010; 50: 377-421.
14. Dibner C, Schibler U, Albrecht U,. The Mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol. 2010; 72: 517-549.
15. Levi F, Schibler U,. Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol. 2007; 47: 593-628.
16. Innominato PF, Levi FA, Bjarnason GA,. Chronotherapy and the molecular clock: clinical implications in oncology. Adv Drug Deliv Rev. 2010; 62: 979-1001.
17. Mormont MC, Waterhouse J, Bleuzen P, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 2000; 6: 3038-3045.
18. Innominato PF, Focan C, Gorlia T, et al. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res. 2009; 69: 4700-4707.
19. Innominato PF, Mormont MC, Rich TA, Waterhouse J, Levi FA, Bjarnason GA,. Circadian disruption, fatigue, and anorexia clustering in advanced cancer patients: implications for innovative therapeutic approaches. Integr Cancer Ther. 2009; 8: 361-370.
20. Waterhouse J, Reilly T, Atkinson G, Edwards B,. Jet lag: trends and coping strategies. Lancet. 2007; 369: 1117-1129.
21. Foster RG, Wulff K,. The rhythm of rest and excess. Nat Rev Neurosci. 2005; 6: 407-414.
22. Innominato PF, Giacchetti S, Bjarnason GA, et al. Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. Int J Cancer. 2012; 131: 2684-2692.
23. Fouladiun M, Korner U, Gunnebo L, Sixt-Ammilon P, Bosaeus I, Lundholm K,. Daily physical-rest activities in relation to nutritional state, metabolism, and quality of life in cancer patients with progressive cachexia. Clin Cancer Res. 2007; 13: 6379-6385.
24. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12: 489-495.
25. Rich T, Innominato PF, Boerner J, et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res. 2005; 11: 1757-1764.
26. Dantzer R, Meagher MW, Cleeland CS,. Translational approaches to treatment-induced symptoms in cancer patients. Nat Rev Clin Oncol. 2012; 9: 414-426.
27. Aprile G, Ramoni M, Keefe D, Sonis S,. Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer. 2008; 112: 284-292.
28. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003; 97: 2919-2925.
29. Mormont MC, Levi F,. Cancer chronotherapy: principles, applications, and perspectives. Cancer. 2003; 97: 155-169.
30. Bjarnason GA, Jordan R,. Rhythms in human gastrointestinal mucosa and skin. Chronobiol Int. 2002; 19: 129-240.
31. Smaaland R, Sothern RB, Laerum OD, Abrahamsen JF,. Rhythms in human bone marrow and blood cells. Chronobiol Int. 2002; 19: 101-127.
32. Kohne CH, Cunningham D, Di CF, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002; 13: 308-317.
33. Sargent DJ, Kohne CH, Sanoff HK, et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in 9 first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol. 2009; 27: 1948-1955.
34. Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009; 10: 865-871.
35. Berger AM, Wielgus KK, Young-McCaughan S, Fischer P, Farr L, Lee KA,. Methodological challenges when using actigraphy in research. J Pain Symptom Manage. 2008; 36: 191-199.